Direct one-pot base-promoted conjugate addition–elimination of 6,8-dibromo-4-chloroquinoline-3-carbaldehyde with methyl mercaptoacetate and subsequent cyclization afforded methyl [(6,8-dibromothieno[3,2-c]quinoline)]-2-carboxylate. The latter undergoes Suzuki-Miyaura cross-coupling with arylboronic acids to yield exclusively the corresponding alkyl [(6,8-diarylthieno[3,2-c]quinoline)]-2-carboxylates,. The cytotoxicity of the prepared compounds was evaluated against the human breast cancer cell line MCF-7 using the MTT assay. The effects of compounds 2, 3c and 4d on cell kinetics were further determined using the xCELLigence Real Time Cell Analysis (RTCA) system. In both the MTT assay and Real Time Cell Analysis, the compounds inhibited cancer cell growth in a dose- and time-dependent manner. Furthermore, on the basis of the calculated LC50 values, the compounds compared favourably with nocodazole, a well-established anticancer drug.
用
巯基乙酸甲酯对 6,8-二
溴-
4-氯喹啉-3-
甲醛进行直接的单锅碱促进共轭加成-消除反应,随后环化得到[(6,8-二
溴噻吩并[3,2-c]
喹啉)]-2-
羧酸甲酯。后者与芳基
硼酸发生 Suzuki-Miyaura 交联反应,完全生成相应的[(6,8-二
溴噻吩并[3,2-c]
喹啉)]-2-
羧酸烷基酯。利用 M
TT 试验评估了所制备化合物对人类乳腺癌细胞株 MCF-7 的细胞毒性。使用 xCELLigence 实时
细胞分析(R
TCA)系统进一步测定了化合物 2、3c 和 4d 对细胞动力学的影响。在 M
TT 试验和实时
细胞分析中,化合物都以剂量和时间依赖性的方式抑制了癌细胞的生长。此外,根据计算得出的半数致死浓度值,这些化合物的效果优于诺柯达唑(一种成熟的抗癌药物)。